Signifor Reduces Risk of Heart Disease, Diabetes in Cushing’s, Study Finds
Treatment with Signifor (pasireotide) for one year reduces the risk for heart disease and diabetes in patients with Cushing’s disease, by improving visceral adiposity index (VAI) scores and adipose tissue dysfunction, according to a multi-center study. However, Signifor did not prevent an increase in cases of diabetes, or change heart disease risk…